Chronic Kidney Disease Drugs Market, by Drug Class (ACE Inhibitors, Angiotensin Receptor Blockers (ARBs), B-Blockers, Calcium Channel Blockers, Loop Diuretics, Erythropoiesis-Stimulating Agents (ESAs), Phosphate Binders, and others), by Route of Administration (Oral, Subcutaneous, Intravenous), by Patient Type (Dialysis, Others) by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)- Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030
Chronic kidney disease is a condition which is characterized by gradual loss of kidney function over time. Chronic kidney disease is also known as chronic renal disease. The kidney disease gets worse, wastes can build to high levels in your blood; other problems associated to chronic kidney disease are high blood pressure, a low red blood cell count, weak bones, poor nutrition, and nerve damage.
The main causes of chronic kidney disease include diabetes, hypertension, chronic glomerulonephritis, chronic pyelonephritis, chronic use of anti-inflammatory medication, autoimmune diseases, polycystic kidney disease, Alport disease, congenital malformations, and prolonged acute renal disease.
Market Dynamics
Key players in market are focused on gaining approvals from regulatory bodies, which is expected to drive the market growth over the forecast period. For instance, in September 2020, Ardelyx, Inc., a biopharmaceutical company focused on developing first-in-class medicines to improve treatment for people with kidney and cardiovascular diseases, announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) of tenapanor for the control of serum phosphorus in adult patients with chronic kidney disease (CKD) on dialysis.
Factors such as awareness initiatives by government bodies, increasing prevalence of chronic kidney disease, and product launches are driving the global chronic kidney disease drugs market growth. For instance, according to an article published by Centers for Disease Control and Prevention in 2021, more than 1 in 7, that is 15% of the U.S. adults or 37 million people, are estimated to have chronic kidney disease. According to same source, chronic kidney disease is more common in people aged 65 years or older (38%) than in people aged 45-64 years (12%) or 18-44 years.
Key features of the study:
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook